Evidence map›Paper›PMID 36497446›Full record

ArticleCancers2022

Good Timing Matters: The Spatially Fractionated High Dose Rate Boost Should Come First.

Elisabeth Schültke, Felix Jaekel, Stefan Bartzsch, Elke Bräuer-Krisch, Herwig Requardt, Jean Albert Laissue, Hans Blattmann, Guido Hildebrandt

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Elisabeth SchültkeDepartment of Radiooncology, Rostock University Medical Center, 18059 Rostock, Germany.
Felix JaekelDepartment of Radiooncology, Rostock University Medical Center, 18059 Rostock, Germany.
Stefan BartzschDepartment of Radiooncology, Technical University of Munich, 81675 Munich, Germany.ORCID 0000-0001-9550-9122
Elke Bräuer-KrischBiomedical Beamline ID 17, European Synchrotron Radiation Facility (ESRF), 38043 Grenoble, France.
Herwig RequardtBiomedical Beamline ID 17, European Synchrotron Radiation Facility (ESRF), 38043 Grenoble, France.
Jean Albert LaissueUniversity of Bern, 3012 Bern, Switzerland.
Hans BlattmannIndependent Researcher, 5417 Untersiggenthal, Switzerland.
Guido HildebrandtDepartment of Radiooncology, Rostock University Medical Center, 18059 Rostock, Germany.
University of Rostock · DEEuropean Synchrotron Radiation Facility · FRHelmholtz Zentrum München · DEMettler-Toledo (Switzerland) · CHUniversity of Bern · CH

Funding

German Research Foundation SCHU 2589/7-1
6 · The paper itself

Abstract

Monoplanar microbeam irradiation (MBI) and pencilbeam irradiation (PBI) are two new concepts of high dose rate radiotherapy, combined with spatial dose fractionation at the micrometre range. In a small animal model, we have explored the concept of integrating MBI or PBI as a simultaneously integrated boost (SIB), either at the beginning or at the end of a conventional, low-dose rate schedule of 5x4 Gy broad beam (BB) whole brain radiotherapy (WBRT). MBI was administered as array of 50 µm wide, quasi-parallel microbeams. For PBI, the target was covered with an array of 50 µm × 50 µm pencilbeams. In both techniques, the centre-to-centre distance was 400 µm. To assure that the entire brain received a dose of at least 4 Gy in all irradiated animals, the peak doses were calculated based on the daily BB fraction to approximate the valley dose. The results of our study have shown that the sequence of the BB irradiation fractions and the microbeam SIB is important to limit the risk of acute adverse effects, including epileptic seizures and death. The microbeam SIB should be integrated early rather than late in the irradiation schedule.

Indexed as

brain tissue tolerancehigh dose rate radiotherapymicrobeam irradiation (MBI)pencilbeam irradiation (PBI)

Identifiers

PMID36497446
PMCPMC9738329
OpenAlexW4311282619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.